Evaluation of venous thromboembolism prophylaxis in cancer patients: A retrospective study

Basit Öğe Kaydı
dc.authorid0000-0002-6141-8676
dc.authorid0000-0002-7636-1393
dc.contributor.authorTaner, Neda
dc.contributor.authorŞirin, Betül
dc.date.accessioned2023-05-24T07:54:25Z
dc.date.available2023-05-24T07:54:25Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Klinik Eczacılık Ana Bilim Dalı
dc.description.abstractThis study aims to evaluate the prophylaxis of venous thromboembolism (VTE) in cancer patients. This retrospective study included 100 adult patients of different ages and genders who applied to the University Hospital between January and November 2021, who were diagnosed with cancer, admitted to the intensive care unit (ICU), and received chemotherapy. The patients were evaluated by clinical pharmacists during their ICU hospital stay in accordance with recommendations from the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the International Society for Thrombosis and Homeostasis Recommendations. Anticoagulant prophylaxis was indicated in all of our patients (100 patients) admitted to the ICU, and 38 (38%) of our patients received anticoagulant prophylaxis during their hospital stay. Enoxaparin sodium was the preferred anticoagulant drug for 38 patients. During outpatient cancer treatment of patients, 27 of our 100 patients had a Khorana risk score greater than 2 and these patients were recommended to receive prophylactic anticoagulant therapy during outpatient treatment. Results of this study showed that, oncology team members should be educated about factors that significantly increase VTE risk, and there is an urgent need to improve VTE awareness and practice of thromboprophylaxis in clinical practice.
dc.identifier.citationTaner, N. ve Şirin, B. (2023). Evaluation of venous thromboembolism prophylaxis in cancer patients: A retrospective study. Acta Pharmaceutica Sciencia, 61(2), 199-212. https://doi.org/10.23893/1307-2080.APS6114
dc.identifier.doi10.23893/1307-2080.APS6114
dc.identifier.endpage212
dc.identifier.issn1307-2080
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85156111522
dc.identifier.scopusqualityQ3
dc.identifier.startpage199
dc.identifier.urihttps://doi.org/10.23893/1307-2080.APS6114
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10968
dc.identifier.volume61
dc.indekslendigikaynakScopus
dc.institutionauthorTaner, Neda
dc.institutionauthorŞirin, Betül
dc.language.isoen
dc.publisherIstanbul Medipol University
dc.relation.ispartofActa Pharmaceutica Scienciaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntico-Agulants
dc.subjectCancer
dc.subjectThromboprophylaxis
dc.subjectVenous Thromboembolism
dc.titleEvaluation of venous thromboembolism prophylaxis in cancer patients: A retrospective study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Taner-Neda-2023.pdf
Boyut:
205.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Eczacılık Fakültesi Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu